Emergency Use Authorization

• 2024

  Log in to bookmark this resource.

  Log in

---

Access Resources

• SummaryEN
• SummaryES
• Ask aRCie About This Resource

About

This webpage summary describes the Emergency Use Authorization (EUA) process by the FDA, which allows unapproved medical products to be used during public health emergencies. It explains how EUAs help protect against threats like chemical or biological agents. The document also covers specific cases, such as COVID-19 and other diseases, where EUAs have been issued for vaccines and diagnostic tests. Additionally, it mentions legal aspects of EUA implementation and related guidance from health authorities to ensure safety and effectiveness in emergency situations.

---

Tags

Focus Areas: CBRNE; Infectious Disease

Audience: Public Health Professionals

Emergency Management Stages: Mitigation; Response

Keywords: Calcimycin; Biological Products; Diagnostic Tests, Routine; United States Food and Drug Administration; Vaccines; Infectious Disease Medicine; Medical Countermeasures; COVID-19 Vaccines

Institutions: U.S. Food and Drug Administration

---

More like this

Drug Trials Snapshots: BEYFORTUS 2024 · U.S. Food and Drug Administration Experimental Studies on Performance of Ventilators Stored in the Strategic National Stockpile 2018 · U.S. Food and Drug Administration, Centers for Disease Control and Prevention (CDC) FDA Briefing Document: Vaccines and Related Biological Products Advisory Committee Meeting 2020 · U.S. Food and Drug Administration, U.S. Department of Health and Human Services (HHS)

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---